ioGlutamatergic Neurons MAPT P301S/WT™


The availability of a quickly maturing, constant, and scalable isogenic system enables learning about frontotemporal dementia (FTD).

ioGlutamatergic Neurons MAPTP301S/WT is known as opti-ox™ precision reprogrammed glutamatergic neurons consisting of a genetically engineered heterozygous P301S mutation in the MAPT gene that is encoding the tau protein.

Also, disease model cells with the MAPT mutation come with a heterozygous N279K mutation (cat no. io1009) and a homozygous P301S mutation (cat no. io1008).


Make true comparisons

It is also possible to pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to instantly examine the effect of mutant tau protein on disease.


Industrial scale quantities come with industry-leading seeding densities, and at a price point enabling the cells to be utilized for research to high throughput screening.


The disease model cells and isogenic control are all set as early as two days post revival, and develop structural neuronal networks at 11 days.


  • FTD research
  • Drug discovery and development
  • Disease modeling
  • Electrophysiological assays (MEA)
  • Co-culture studies

Other Equipment by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.